tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Psoriasis D011565 47 associated lipids
Precancerous Conditions D011230 48 associated lipids
Fatty Liver D005234 48 associated lipids
Thrombosis D013927 49 associated lipids
Osteosarcoma D012516 50 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Weight Loss D015431 56 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Shihab FS et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. 2008 Transplantation pmid:18475181
Shivaswamy V et al. Tacrolimus and sirolimus induce reproductive abnormalities in female rats. 2011 Transplantation pmid:21508897
Miyauchi T et al. Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation. 1998 Transplantation pmid:9448139
Rosen HR et al. Significance of early aminotransferase elevation after liver transplantation. 1998 Transplantation pmid:9448146
David-Neto E et al. Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. 2017 Transplantation pmid:27798513
McCune TR et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. 1998 Transplantation pmid:9448150
Mentzer RM et al. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. 1998 Transplantation pmid:9448154
Koprak S et al. Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. 1996 Transplantation pmid:8623162
First MR Transplantation in the nineties. 1992 Transplantation pmid:1370734
Prókai Á et al. Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. 2016 Transplantation pmid:26502369
Khanafer A et al. Increased nitric oxide production during acute rejection in kidney transplantation: a useful marker to aid in the diagnosis of rejection. 2007 Transplantation pmid:17876269
Calmus Y et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. 2010 Transplantation pmid:20495510
Egli A et al. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. 2009 Transplantation pmid:19935369
Selzner N et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. 2009 Transplantation pmid:19935376
Rush DN et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. 2009 Transplantation pmid:19935461
Lee D et al. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. 2017 Transplantation pmid:27779572
Khanna A et al. Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow. 1998 Transplantation pmid:9500620
Wozniak LJ et al. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. 2015 Transplantation pmid:26038872
Gayowski T et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. 1998 Transplantation pmid:9500623
Neylan JF Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. 1998 Transplantation pmid:9500626
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
Kim YI et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. 1992 Transplantation pmid:1373539
Cosio FG et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. 2007 Transplantation pmid:17318073
Budde K et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. 2007 Transplantation pmid:17318074
D'Antiga L et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. 2002 Transplantation pmid:11792983
Butani L et al. Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. 2002 Transplantation pmid:11793001
Leung W et al. Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. 1999 Transplantation pmid:10385092
Propper DJ et al. FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. 1990 Transplantation pmid:1696409
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Gupta A et al. Elevated myeloid: plasmacytoid dendritic cell ratio associates with late, but not early, liver rejection in children induced with rabbit anti-human thymocyte globulin. 2009 Transplantation pmid:19696644
Shibutani S et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. 2005 Transplantation pmid:15849542
Jain A et al. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. 2008 Transplantation pmid:18347534
Ciancio G et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. 2002 Transplantation pmid:11965039
Khanna A et al. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. 1999 Transplantation pmid:10071036
Kessler M et al. A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. 1999 Transplantation pmid:10071045
Johansson A and Möller E Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. 1990 Transplantation pmid:1701570
Guo Z et al. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. 1997 Transplantation pmid:9075844
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518974
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Platz KP et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518975
Takaya S et al. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. 1992 Transplantation pmid:1279851
van Rijen MM et al. CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. 2002 Transplantation pmid:12042657
Horner BM et al. Recipient damage after musculocutaneous transplant rejection. 2008 Transplantation pmid:18946349
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
di Francesco F et al. One year follow-up of steroid-free immunosuppression plus everolimus in isolated pancreas transplantation. 2008 Transplantation pmid:18946356
Levitsky J et al. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. 2011 Transplantation pmid:21239962
Bäckman L et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. 1994 Transplantation pmid:7509516
Higgins RM et al. Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. 2004 Transplantation pmid:14966430
Mahé E et al. Drug-induced hypersensitivity syndrome associated with primary Epstein-Barr virus and human herpesvirus 6 infections in a child intestinal transplant recipient. 2004 Transplantation pmid:14966435
Paramesh AS et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. 2004 Transplantation pmid:14724447
Boillot O et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. 1998 Transplantation pmid:9825815
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Jain AB et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. 1998 Transplantation pmid:9825817
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Franz M et al. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? 1998 Transplantation pmid:9825827
Mathis AS et al. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. 2001 Transplantation pmid:11374405
Abadja F et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. 2011 Transplantation pmid:21818055
Jain AB et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. 1998 Transplantation pmid:9846530
Takatsuki M et al. Weaning of immunosuppression in living donor liver transplant recipients. 2001 Transplantation pmid:11502975
Watson MJ et al. Renal function impacts outcomes after intestinal transplantation. 2008 Transplantation pmid:18622288
Poncelet AJ et al. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus. 2008 Transplantation pmid:19077894
Uchida N et al. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. 2011 Transplantation pmid:21677598
Mourad M et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. 2005 Transplantation pmid:16249748
Ciancio G et al. Review of major clinical trials with mycophenolate mofetil in renal transplantation. 2005 Transplantation pmid:16251852
Iwata H et al. Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. 1993 Transplantation pmid:7687396
Hariharan S Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs). 2002 Transplantation pmid:12357988
Wu MJ et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. 2011 Transplantation pmid:21912349
Stempfle HU et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. 2002 Transplantation pmid:11889427
Vafadari R et al. Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry. 2012 Transplantation pmid:22643331
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Schena FP et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. 2009 Transplantation pmid:19155978
Morales JM et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. 2008 Transplantation pmid:18724234
Opelz G and Döhler B Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. 2008 Transplantation pmid:18698238
Muraki T et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. 1995 Transplantation pmid:7544038
Fridell JA et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. 2002 Transplantation pmid:12499888
Oike F et al. A 12-day course of FK506 allows long-term acceptance of semi-identical liver allograft in inbred miniature swine. 2000 Transplantation pmid:10868630
Gloor JM et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. 2002 Transplantation pmid:12131699
Aw MM et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. 2003 Transplantation pmid:12660504
Charpentier B et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. 2003 Transplantation pmid:12660513
Hebert MF et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. 2013 Transplantation pmid:23274970
Molmenti EP et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. 2001 Transplantation pmid:11213072
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Thai NL et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. 2006 Transplantation pmid:17198253
Armitage JM et al. Preliminary experience with FK506 in thoracic transplantation. 1991 Transplantation pmid:1713363
Ueki S et al. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. 2006 Transplantation pmid:17198266
Jain A et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. 2011 Transplantation pmid:21378604
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Gruessner RW et al. Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. 2004 Transplantation pmid:15239611
Macphee IA et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. 2005 Transplantation pmid:15729180
Bendahan J et al. The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. 1994 Transplantation pmid:7511255
Baggio B et al. Relationship between plasma phospholipid polyunsaturated fatty acid composition and bone disease in renal transplantation. 2005 Transplantation pmid:16314806
Margreiter R et al. A double-hand transplant can be worth the effort! 2002 Transplantation pmid:12134104
Tian L et al. Association of the CD134/CD134L costimulatory pathway with acute rejection of small bowel allograft. 2002 Transplantation pmid:12134113
Krämer BK et al. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. 2012 Transplantation pmid:22858806
Wiesner RH A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. 1998 Transplantation pmid:9734494
Hodak SP et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. 1998 Transplantation pmid:9734501